Repros Therapeutics (RPRX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
November 8, 2016 4:00 PM ESTTHE WOODLANDS, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced financial results for the third quarter ended September 30, 2016.
Financial Results
Net loss for the three month period ended September 30, 2016, was ($4.2) million or ($0.17) per share as compared to a net loss of ($6.6) million or ($0.27) per share for the same period in 2015. The net loss for the nine month period ended September 30, 2016, was ($13.3) million or ($0.55) per share as compared to a net loss of ($22.9) million or ($0.94) per... More
